<?xml version="1.0" encoding="UTF-8"?>
<rss version="2.0"
	xmlns:content="http://purl.org/rss/1.0/modules/content/"
	xmlns:wfw="http://wellformedweb.org/CommentAPI/"
	xmlns:dc="http://purl.org/dc/elements/1.1/"
	xmlns:atom="http://www.w3.org/2005/Atom"
	xmlns:sy="http://purl.org/rss/1.0/modules/syndication/"
	xmlns:slash="http://purl.org/rss/1.0/modules/slash/"
	>

<channel>
	<title>PILMAN &#187; Open</title>
	<atom:link href="http://www.tapanray.in/tag/open/feed/" rel="self" type="application/rss+xml" />
	<link>http://www.tapanray.in</link>
	<description>A Tapan Ray Website</description>
	<lastBuildDate>Sun, 22 Mar 2026 10:59:18 +0000</lastBuildDate>
	<language>en-US</language>
	<sy:updatePeriod>hourly</sy:updatePeriod>
	<sy:updateFrequency>1</sy:updateFrequency>
	<generator>http://wordpress.org/?v=3.4.2</generator>
		<item>
		<title>Unleashing Pharma’s New Potential In Changing Market Dynamics</title>
		<link>http://www.tapanray.in/unleashing-pharmas-new-potential-in-changing-market-dynamics/?utm_source=rss&#038;utm_medium=rss&#038;utm_campaign=unleashing-pharmas-new-potential-in-changing-market-dynamics</link>
		<comments>http://www.tapanray.in/unleashing-pharmas-new-potential-in-changing-market-dynamics/#comments</comments>
		<pubDate>Mon, 07 Jun 2021 00:00:32 +0000</pubDate>
		<dc:creator>Tapan Ray</dc:creator>
				<category><![CDATA[Pharma]]></category>
		<category><![CDATA[Amgen]]></category>
		<category><![CDATA[changing]]></category>
		<category><![CDATA[COVID-19]]></category>
		<category><![CDATA[digital]]></category>
		<category><![CDATA[dynamics]]></category>
		<category><![CDATA[EliLilly]]></category>
		<category><![CDATA[India]]></category>
		<category><![CDATA[market]]></category>
		<category><![CDATA[Novartis]]></category>
		<category><![CDATA[Open]]></category>
		<category><![CDATA[pandemic]]></category>
		<category><![CDATA[Pfizer]]></category>
		<category><![CDATA[plan]]></category>
		<category><![CDATA[potential]]></category>
		<category><![CDATA[Ray]]></category>
		<category><![CDATA[remote working]]></category>
		<category><![CDATA[Sun Pharma]]></category>
		<category><![CDATA[Tapan]]></category>
		<category><![CDATA[Tapan Ray]]></category>
		<category><![CDATA[TCS]]></category>
		<category><![CDATA[unleashing]]></category>
		<category><![CDATA[WFH]]></category>
		<category><![CDATA[work from home]]></category>
		<category><![CDATA[workplace]]></category>

		<guid isPermaLink="false">http://www.tapanray.in/?p=10525</guid>
		<description><![CDATA[Several pharma majors have started pondering in this space. This is evident from several recent developments, both in India, and also in other places of the world. One such articulation can be heard from the very top of the domestic &#8230; <a href="http://www.tapanray.in/unleashing-pharmas-new-potential-in-changing-market-dynamics/">Continue reading <span class="meta-nav">&#8594;</span></a>]]></description>
		<wfw:commentRss>http://www.tapanray.in/unleashing-pharmas-new-potential-in-changing-market-dynamics/feed/</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>Awaiting The Two To Tango: Pharma Innovation And Public Health Interest</title>
		<link>http://www.tapanray.in/awaiting-the-two-to-tango-pharma-innovation-and-public-health-interest/?utm_source=rss&#038;utm_medium=rss&#038;utm_campaign=awaiting-the-two-to-tango-pharma-innovation-and-public-health-interest</link>
		<comments>http://www.tapanray.in/awaiting-the-two-to-tango-pharma-innovation-and-public-health-interest/#comments</comments>
		<pubDate>Mon, 02 Jan 2017 00:00:28 +0000</pubDate>
		<dc:creator>Tapan Ray</dc:creator>
				<category><![CDATA[Pharma]]></category>
		<category><![CDATA[Africa]]></category>
		<category><![CDATA[awaiting]]></category>
		<category><![CDATA[countries]]></category>
		<category><![CDATA[developed]]></category>
		<category><![CDATA[Developing]]></category>
		<category><![CDATA[discovery]]></category>
		<category><![CDATA[disease]]></category>
		<category><![CDATA[Drug]]></category>
		<category><![CDATA[expectancy]]></category>
		<category><![CDATA[Health]]></category>
		<category><![CDATA[Healthcare]]></category>
		<category><![CDATA[high]]></category>
		<category><![CDATA[IGWG]]></category>
		<category><![CDATA[India]]></category>
		<category><![CDATA[innovation]]></category>
		<category><![CDATA[interest]]></category>
		<category><![CDATA[life]]></category>
		<category><![CDATA[Medicines]]></category>
		<category><![CDATA[NSSO]]></category>
		<category><![CDATA[Open]]></category>
		<category><![CDATA[OSDD]]></category>
		<category><![CDATA[patented]]></category>
		<category><![CDATA[pricey]]></category>
		<category><![CDATA[public]]></category>
		<category><![CDATA[R&D]]></category>
		<category><![CDATA[Ray]]></category>
		<category><![CDATA[source]]></category>
		<category><![CDATA[tango]]></category>
		<category><![CDATA[Tapan]]></category>
		<category><![CDATA[Tapan Ray]]></category>
		<category><![CDATA[tropical]]></category>
		<category><![CDATA[two]]></category>

		<guid isPermaLink="false">http://www.tapanray.in/?p=8029</guid>
		<description><![CDATA[“The rewards for the breakthrough drug discovery must be substantial, but if prices are the only mechanism through which returns on research flow, affordability will be compromised,” articulated an article titled, ‘Pharmaceutical Policy Reform &#8211; Balancing Affordability with Incentives for Innovation’, &#8230; <a href="http://www.tapanray.in/awaiting-the-two-to-tango-pharma-innovation-and-public-health-interest/">Continue reading <span class="meta-nav">&#8594;</span></a>]]></description>
		<wfw:commentRss>http://www.tapanray.in/awaiting-the-two-to-tango-pharma-innovation-and-public-health-interest/feed/</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>Patented Drugs: A Dangerous Pricing Trend Impacting Patient Access</title>
		<link>http://www.tapanray.in/patented-drugs-a-dangerous-pricing-trend-impacting-patient-access/?utm_source=rss&#038;utm_medium=rss&#038;utm_campaign=patented-drugs-a-dangerous-pricing-trend-impacting-patient-access</link>
		<comments>http://www.tapanray.in/patented-drugs-a-dangerous-pricing-trend-impacting-patient-access/#comments</comments>
		<pubDate>Mon, 11 Jul 2016 00:00:10 +0000</pubDate>
		<dc:creator>Tapan Ray</dc:creator>
				<category><![CDATA[Pharma]]></category>
		<category><![CDATA[2012]]></category>
		<category><![CDATA[3d]]></category>
		<category><![CDATA[Act]]></category>
		<category><![CDATA[dangerous]]></category>
		<category><![CDATA[Daniel]]></category>
		<category><![CDATA[database]]></category>
		<category><![CDATA[doctor]]></category>
		<category><![CDATA[drugs]]></category>
		<category><![CDATA[India]]></category>
		<category><![CDATA[Indian]]></category>
		<category><![CDATA[irresponsible]]></category>
		<category><![CDATA[License]]></category>
		<category><![CDATA[NPPP]]></category>
		<category><![CDATA[Open]]></category>
		<category><![CDATA[out of pocket]]></category>
		<category><![CDATA[patented]]></category>
		<category><![CDATA[Payment]]></category>
		<category><![CDATA[Pricing]]></category>
		<category><![CDATA[profits]]></category>
		<category><![CDATA[ptent]]></category>
		<category><![CDATA[Ray]]></category>
		<category><![CDATA[section]]></category>
		<category><![CDATA[solution]]></category>
		<category><![CDATA[Sovaldi]]></category>
		<category><![CDATA[Stone]]></category>
		<category><![CDATA[Tapan]]></category>
		<category><![CDATA[Tapan Ray]]></category>
		<category><![CDATA[trend]]></category>
		<category><![CDATA[VL]]></category>
		<category><![CDATA[Voluntary]]></category>
		<category><![CDATA[Windfall]]></category>

		<guid isPermaLink="false">http://www.tapanray.in/?p=7721</guid>
		<description><![CDATA[The upcoming trend of jaw dropping high prices for new patented drugs sends a ‘storm signal’ to many stakeholders, especially for its adverse impact on patient access. Even more intriguing, such high and insane prices are being fixed rather arbitrarily, &#8230; <a href="http://www.tapanray.in/patented-drugs-a-dangerous-pricing-trend-impacting-patient-access/">Continue reading <span class="meta-nav">&#8594;</span></a>]]></description>
		<wfw:commentRss>http://www.tapanray.in/patented-drugs-a-dangerous-pricing-trend-impacting-patient-access/feed/</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>The Curious Conundrum of New Drugs Approval Process</title>
		<link>http://www.tapanray.in/the-curious-conundrum-of-new-drugs-approval-process/?utm_source=rss&#038;utm_medium=rss&#038;utm_campaign=the-curious-conundrum-of-new-drugs-approval-process</link>
		<comments>http://www.tapanray.in/the-curious-conundrum-of-new-drugs-approval-process/#comments</comments>
		<pubDate>Mon, 18 Jan 2016 00:00:05 +0000</pubDate>
		<dc:creator>Tapan Ray</dc:creator>
				<category><![CDATA[Pharma]]></category>
		<category><![CDATA[Alatrofloxacin]]></category>
		<category><![CDATA[approval]]></category>
		<category><![CDATA[Aprotinin]]></category>
		<category><![CDATA[big]]></category>
		<category><![CDATA[BMJ]]></category>
		<category><![CDATA[Canada]]></category>
		<category><![CDATA[CDC]]></category>
		<category><![CDATA[Clinical]]></category>
		<category><![CDATA[Cochrane]]></category>
		<category><![CDATA[collaboration]]></category>
		<category><![CDATA[conundrum]]></category>
		<category><![CDATA[curious]]></category>
		<category><![CDATA[data]]></category>
		<category><![CDATA[disclosure]]></category>
		<category><![CDATA[Drotrecogin alfa]]></category>
		<category><![CDATA[drugs]]></category>
		<category><![CDATA[Economist]]></category>
		<category><![CDATA[EFPIA]]></category>
		<category><![CDATA[EMA]]></category>
		<category><![CDATA[FDA]]></category>
		<category><![CDATA[full]]></category>
		<category><![CDATA[Health]]></category>
		<category><![CDATA[India]]></category>
		<category><![CDATA[International]]></category>
		<category><![CDATA[London]]></category>
		<category><![CDATA[Lumiracoxib]]></category>
		<category><![CDATA[marketing]]></category>
		<category><![CDATA[Matthew Herder]]></category>
		<category><![CDATA[New]]></category>
		<category><![CDATA[Open]]></category>
		<category><![CDATA[platform]]></category>
		<category><![CDATA[process]]></category>
		<category><![CDATA[Propoxyphene]]></category>
		<category><![CDATA[public]]></category>
		<category><![CDATA[Ray]]></category>
		<category><![CDATA[registry]]></category>
		<category><![CDATA[Regulatory]]></category>
		<category><![CDATA[Rofecoxib]]></category>
		<category><![CDATA[Rosiglitazone]]></category>
		<category><![CDATA[Safety]]></category>
		<category><![CDATA[Sibutramine]]></category>
		<category><![CDATA[Tamiflu]]></category>
		<category><![CDATA[Tapan]]></category>
		<category><![CDATA[Tapan Ray]]></category>
		<category><![CDATA[Tegaserod]]></category>
		<category><![CDATA[Tetrazepam]]></category>
		<category><![CDATA[Trial]]></category>
		<category><![CDATA[Trials]]></category>
		<category><![CDATA[US]]></category>
		<category><![CDATA[Vioxx]]></category>
		<category><![CDATA[W.H.O]]></category>
		<category><![CDATA[WHO]]></category>

		<guid isPermaLink="false">http://www.tapanray.in/?p=7360</guid>
		<description><![CDATA[Fathoming the details of just a short span of time, not going beyond the last 10 years, I find from the published data that many new drugs, such as, Alatrofloxacin, Aprotinin, Drotrecogin alfa, Lumiracoxib, Propoxyphene, Rofecoxib, Rosiglitazone, Sibutramine, Tegaserod, Tetrazepam, were &#8230; <a href="http://www.tapanray.in/the-curious-conundrum-of-new-drugs-approval-process/">Continue reading <span class="meta-nav">&#8594;</span></a>]]></description>
		<wfw:commentRss>http://www.tapanray.in/the-curious-conundrum-of-new-drugs-approval-process/feed/</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>New “National IPR Policy” of India – A Pharma Perspective</title>
		<link>http://www.tapanray.in/new-national-ipr-policy-of-india-a-pharma-perspective/?utm_source=rss&#038;utm_medium=rss&#038;utm_campaign=new-national-ipr-policy-of-india-a-pharma-perspective</link>
		<comments>http://www.tapanray.in/new-national-ipr-policy-of-india-a-pharma-perspective/#comments</comments>
		<pubDate>Mon, 19 Jan 2015 00:00:06 +0000</pubDate>
		<dc:creator>Tapan Ray</dc:creator>
				<category><![CDATA[Pharma]]></category>
		<category><![CDATA[301]]></category>
		<category><![CDATA[CL]]></category>
		<category><![CDATA[Congress]]></category>
		<category><![CDATA[data]]></category>
		<category><![CDATA[DIPP]]></category>
		<category><![CDATA[Exclusivity]]></category>
		<category><![CDATA[Gilead]]></category>
		<category><![CDATA[Government]]></category>
		<category><![CDATA[Hatch]]></category>
		<category><![CDATA[Index]]></category>
		<category><![CDATA[India]]></category>
		<category><![CDATA[innovation]]></category>
		<category><![CDATA[Intellectual]]></category>
		<category><![CDATA[IP]]></category>
		<category><![CDATA[IPR]]></category>
		<category><![CDATA[Justice]]></category>
		<category><![CDATA[lawmakers]]></category>
		<category><![CDATA[MNC]]></category>
		<category><![CDATA[National]]></category>
		<category><![CDATA[OCR]]></category>
		<category><![CDATA[Open]]></category>
		<category><![CDATA[Orrin]]></category>
		<category><![CDATA[Patent]]></category>
		<category><![CDATA[perspective]]></category>
		<category><![CDATA[pharmaceutical]]></category>
		<category><![CDATA[PhRMA]]></category>
		<category><![CDATA[Policy]]></category>
		<category><![CDATA[Prabha]]></category>
		<category><![CDATA[Property]]></category>
		<category><![CDATA[Protection]]></category>
		<category><![CDATA[Ray]]></category>
		<category><![CDATA[Regulatory]]></category>
		<category><![CDATA[Report]]></category>
		<category><![CDATA[Rights]]></category>
		<category><![CDATA[Senator]]></category>
		<category><![CDATA[sofosbuvir]]></category>
		<category><![CDATA[Sovaldi]]></category>
		<category><![CDATA[Special]]></category>
		<category><![CDATA[Sridevan]]></category>
		<category><![CDATA[Tank]]></category>
		<category><![CDATA[Tapan]]></category>
		<category><![CDATA[Tapan Ray]]></category>
		<category><![CDATA[Think]]></category>
		<category><![CDATA[TPF]]></category>
		<category><![CDATA[US]]></category>
		<category><![CDATA[USTR]]></category>

		<guid isPermaLink="false">http://www.tapanray.in/?p=6330</guid>
		<description><![CDATA[Whether under pressure or not, is hardly of any relevance now. What is relevant today is the fact that the new Indian Government, almost in a record time of just around two months, has been able to release a high &#8230; <a href="http://www.tapanray.in/new-national-ipr-policy-of-india-a-pharma-perspective/">Continue reading <span class="meta-nav">&#8594;</span></a>]]></description>
		<wfw:commentRss>http://www.tapanray.in/new-national-ipr-policy-of-india-a-pharma-perspective/feed/</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>Patented Drug Pricing: Relevance To R&amp;D Investments</title>
		<link>http://www.tapanray.in/patented-drug-pricing-relevance-to-rd-investments/?utm_source=rss&#038;utm_medium=rss&#038;utm_campaign=patented-drug-pricing-relevance-to-rd-investments</link>
		<comments>http://www.tapanray.in/patented-drug-pricing-relevance-to-rd-investments/#comments</comments>
		<pubDate>Mon, 18 Aug 2014 00:00:10 +0000</pubDate>
		<dc:creator>Tapan Ray</dc:creator>
				<category><![CDATA[Pharma]]></category>
		<category><![CDATA[Access]]></category>
		<category><![CDATA[AMP]]></category>
		<category><![CDATA[brain]]></category>
		<category><![CDATA[Drug]]></category>
		<category><![CDATA[Gilead]]></category>
		<category><![CDATA[Government]]></category>
		<category><![CDATA[India]]></category>
		<category><![CDATA[innovation]]></category>
		<category><![CDATA[investments]]></category>
		<category><![CDATA[IPR]]></category>
		<category><![CDATA[Open]]></category>
		<category><![CDATA[patented]]></category>
		<category><![CDATA[Pharmaceuticals]]></category>
		<category><![CDATA[Pricing]]></category>
		<category><![CDATA[public]]></category>
		<category><![CDATA[Ray]]></category>
		<category><![CDATA[relevance R&D]]></category>
		<category><![CDATA[smarter]]></category>
		<category><![CDATA[Social]]></category>
		<category><![CDATA[Sovaldi]]></category>
		<category><![CDATA[Tapan]]></category>
		<category><![CDATA[USFDA]]></category>

		<guid isPermaLink="false">http://www.tapanray.in/?p=5766</guid>
		<description><![CDATA[The costs of most of the new life saving drugs, used in the treatment of dreaded diseases such as cancer, have now started going north at a brisk pace, more than ever before. From the global pharma industry perspective, the &#8230; <a href="http://www.tapanray.in/patented-drug-pricing-relevance-to-rd-investments/">Continue reading <span class="meta-nav">&#8594;</span></a>]]></description>
		<wfw:commentRss>http://www.tapanray.in/patented-drug-pricing-relevance-to-rd-investments/feed/</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>Is Drug Innovation As Critical As Access To Medicines For All? [Augmented By A Video]</title>
		<link>http://www.tapanray.in/is-drug-innovation-as-critical-as-access-to-medicines-for-all-augmented-by-a-video/?utm_source=rss&#038;utm_medium=rss&#038;utm_campaign=is-drug-innovation-as-critical-as-access-to-medicines-for-all-augmented-by-a-video</link>
		<comments>http://www.tapanray.in/is-drug-innovation-as-critical-as-access-to-medicines-for-all-augmented-by-a-video/#comments</comments>
		<pubDate>Mon, 12 May 2014 00:00:44 +0000</pubDate>
		<dc:creator>Tapan Ray</dc:creator>
				<category><![CDATA[Pharma]]></category>
		<category><![CDATA[accelerating]]></category>
		<category><![CDATA[Access]]></category>
		<category><![CDATA[AMP]]></category>
		<category><![CDATA[brain]]></category>
		<category><![CDATA[center]]></category>
		<category><![CDATA[clipping]]></category>
		<category><![CDATA[Cost]]></category>
		<category><![CDATA[credibility]]></category>
		<category><![CDATA[critical]]></category>
		<category><![CDATA[Demythologizing]]></category>
		<category><![CDATA[Drug]]></category>
		<category><![CDATA[dubious]]></category>
		<category><![CDATA[Fund]]></category>
		<category><![CDATA[have-nots]]></category>
		<category><![CDATA[Health]]></category>
		<category><![CDATA[IMPACT]]></category>
		<category><![CDATA[India]]></category>
		<category><![CDATA[innovation]]></category>
		<category><![CDATA[logjam.]]></category>
		<category><![CDATA[Medicines]]></category>
		<category><![CDATA[model]]></category>
		<category><![CDATA[Open]]></category>
		<category><![CDATA[Partnership]]></category>
		<category><![CDATA[perpetuity]]></category>
		<category><![CDATA[pharmaceutical]]></category>
		<category><![CDATA[Pogge]]></category>
		<category><![CDATA[PPP]]></category>
		<category><![CDATA[R&D]]></category>
		<category><![CDATA[Ray]]></category>
		<category><![CDATA[rich]]></category>
		<category><![CDATA[smarter]]></category>
		<category><![CDATA[Social]]></category>
		<category><![CDATA[source]]></category>
		<category><![CDATA[Tapan]]></category>
		<category><![CDATA[Thomas]]></category>
		<category><![CDATA[Tuft]]></category>
		<category><![CDATA[Universal]]></category>
		<category><![CDATA[video]]></category>

		<guid isPermaLink="false">http://www.tapanray.in/?p=5372</guid>
		<description><![CDATA[To make important medicines available to all in a sustainable way, the renowned philosopher Thomas Pogge in this very interesting video clipping titled “Medicines For The 99 Percent” suggested the following three simple, yet critical, steps to effectively run the &#8230; <a href="http://www.tapanray.in/is-drug-innovation-as-critical-as-access-to-medicines-for-all-augmented-by-a-video/">Continue reading <span class="meta-nav">&#8594;</span></a>]]></description>
		<wfw:commentRss>http://www.tapanray.in/is-drug-innovation-as-critical-as-access-to-medicines-for-all-augmented-by-a-video/feed/</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>A Potential Game Changer For Pharma R&amp;D</title>
		<link>http://www.tapanray.in/a-potential-game-changer-for-pharma-rd/?utm_source=rss&#038;utm_medium=rss&#038;utm_campaign=a-potential-game-changer-for-pharma-rd</link>
		<comments>http://www.tapanray.in/a-potential-game-changer-for-pharma-rd/#comments</comments>
		<pubDate>Mon, 10 Feb 2014 00:00:35 +0000</pubDate>
		<dc:creator>Tapan Ray</dc:creator>
				<category><![CDATA[Pharma]]></category>
		<category><![CDATA[Abdul]]></category>
		<category><![CDATA[Alzheimer's]]></category>
		<category><![CDATA[AMP]]></category>
		<category><![CDATA[big]]></category>
		<category><![CDATA[biomarkers]]></category>
		<category><![CDATA[Changer]]></category>
		<category><![CDATA[chris]]></category>
		<category><![CDATA[cliff]]></category>
		<category><![CDATA[Collaborative]]></category>
		<category><![CDATA[CSIR]]></category>
		<category><![CDATA[Game]]></category>
		<category><![CDATA[GSK]]></category>
		<category><![CDATA[India]]></category>
		<category><![CDATA[IPR]]></category>
		<category><![CDATA[kalam]]></category>
		<category><![CDATA[Merck]]></category>
		<category><![CDATA[NIH]]></category>
		<category><![CDATA[OHE]]></category>
		<category><![CDATA[Open]]></category>
		<category><![CDATA[OSDD]]></category>
		<category><![CDATA[Patent]]></category>
		<category><![CDATA[Pharmaceuticals]]></category>
		<category><![CDATA[potential]]></category>
		<category><![CDATA[PPP]]></category>
		<category><![CDATA[R&D]]></category>
		<category><![CDATA[Ray]]></category>
		<category><![CDATA[Sanofi]]></category>
		<category><![CDATA[source]]></category>
		<category><![CDATA[Tapan]]></category>
		<category><![CDATA[UK]]></category>
		<category><![CDATA[US]]></category>
		<category><![CDATA[viehbacher]]></category>

		<guid isPermaLink="false">http://www.tapanray.in/?p=4974</guid>
		<description><![CDATA[The ghost of ‘Patent Cliff’ has been haunting the ‘Big Pharma’ since quite some time. This situation has been further aggravated by cost containment pressures of various Governments both in the developed and the emerging markets together with contentious issues &#8230; <a href="http://www.tapanray.in/a-potential-game-changer-for-pharma-rd/">Continue reading <span class="meta-nav">&#8594;</span></a>]]></description>
		<wfw:commentRss>http://www.tapanray.in/a-potential-game-changer-for-pharma-rd/feed/</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>Big Pharma Demands Transparency, Keeping their &#8216;Black-Boxes&#8217; Tight and Safe?</title>
		<link>http://www.tapanray.in/big-pharma-demands-transparency-keeping-their-black-boxes-tight-and-safe/?utm_source=rss&#038;utm_medium=rss&#038;utm_campaign=big-pharma-demands-transparency-keeping-their-black-boxes-tight-and-safe</link>
		<comments>http://www.tapanray.in/big-pharma-demands-transparency-keeping-their-black-boxes-tight-and-safe/#comments</comments>
		<pubDate>Mon, 28 Oct 2013 00:00:21 +0000</pubDate>
		<dc:creator>Tapan Ray</dc:creator>
				<category><![CDATA[Pharma]]></category>
		<category><![CDATA[Act]]></category>
		<category><![CDATA[affordable]]></category>
		<category><![CDATA[America]]></category>
		<category><![CDATA[Black]]></category>
		<category><![CDATA[box]]></category>
		<category><![CDATA[care]]></category>
		<category><![CDATA[Clinical]]></category>
		<category><![CDATA[companies]]></category>
		<category><![CDATA[drugs]]></category>
		<category><![CDATA[DTC]]></category>
		<category><![CDATA[expenditure]]></category>
		<category><![CDATA[Facts]]></category>
		<category><![CDATA[Free]]></category>
		<category><![CDATA[ghostwriting]]></category>
		<category><![CDATA[global]]></category>
		<category><![CDATA[governance]]></category>
		<category><![CDATA[Guidelines]]></category>
		<category><![CDATA[Health]]></category>
		<category><![CDATA[industry]]></category>
		<category><![CDATA[innovation]]></category>
		<category><![CDATA[innovator]]></category>
		<category><![CDATA[interest]]></category>
		<category><![CDATA[lobbying]]></category>
		<category><![CDATA[Making]]></category>
		<category><![CDATA[need]]></category>
		<category><![CDATA[NYT]]></category>
		<category><![CDATA[Obama]]></category>
		<category><![CDATA[Open]]></category>
		<category><![CDATA[patented]]></category>
		<category><![CDATA[pharmaceutical]]></category>
		<category><![CDATA[PhRMA]]></category>
		<category><![CDATA[placebo]]></category>
		<category><![CDATA[Policies]]></category>
		<category><![CDATA[population]]></category>
		<category><![CDATA[predictable]]></category>
		<category><![CDATA[President]]></category>
		<category><![CDATA[Pricing]]></category>
		<category><![CDATA[public]]></category>
		<category><![CDATA[R&D]]></category>
		<category><![CDATA[Ray]]></category>
		<category><![CDATA[revelation]]></category>
		<category><![CDATA[safe]]></category>
		<category><![CDATA[samples]]></category>
		<category><![CDATA[secret]]></category>
		<category><![CDATA[sponsorship]]></category>
		<category><![CDATA[striking]]></category>
		<category><![CDATA[Tapan]]></category>
		<category><![CDATA[tight]]></category>
		<category><![CDATA[transparency]]></category>
		<category><![CDATA[Trial]]></category>
		<category><![CDATA[USFDA]]></category>
		<category><![CDATA[wasteful]]></category>

		<guid isPermaLink="false">http://www.tapanray.in/?p=2780</guid>
		<description><![CDATA[Pharmaceutical Industry across the globe wants absolute transparency in all government laws, policies, guidelines, transactions and overall governance. They also expect the trade environment should be predictable, non-manipulative and business-friendly. These expectations are indeed well justified and deserve whole-hearted support &#8230; <a href="http://www.tapanray.in/big-pharma-demands-transparency-keeping-their-black-boxes-tight-and-safe/">Continue reading <span class="meta-nav">&#8594;</span></a>]]></description>
		<wfw:commentRss>http://www.tapanray.in/big-pharma-demands-transparency-keeping-their-black-boxes-tight-and-safe/feed/</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>R&amp;D: Is Indian Pharma Moving Up the Value Chain?</title>
		<link>http://www.tapanray.in/rd-is-indian-pharma-moving-up-the-value-chain/?utm_source=rss&#038;utm_medium=rss&#038;utm_campaign=rd-is-indian-pharma-moving-up-the-value-chain</link>
		<comments>http://www.tapanray.in/rd-is-indian-pharma-moving-up-the-value-chain/#comments</comments>
		<pubDate>Mon, 02 Sep 2013 00:00:29 +0000</pubDate>
		<dc:creator>Tapan Ray</dc:creator>
				<category><![CDATA[Pharma]]></category>
		<category><![CDATA[acquisition]]></category>
		<category><![CDATA[agreement]]></category>
		<category><![CDATA[analogue]]></category>
		<category><![CDATA[arbitrage]]></category>
		<category><![CDATA[AstraZeneca]]></category>
		<category><![CDATA[bharat]]></category>
		<category><![CDATA[Biocon]]></category>
		<category><![CDATA[Biotech]]></category>
		<category><![CDATA[BMS]]></category>
		<category><![CDATA[Brownfield]]></category>
		<category><![CDATA[Cadilla]]></category>
		<category><![CDATA[chain]]></category>
		<category><![CDATA[collaboration]]></category>
		<category><![CDATA[Cost]]></category>
		<category><![CDATA[critical]]></category>
		<category><![CDATA[CSIR]]></category>
		<category><![CDATA[DBT]]></category>
		<category><![CDATA[deal]]></category>
		<category><![CDATA[diabetic]]></category>
		<category><![CDATA[Dr]]></category>
		<category><![CDATA[DRL]]></category>
		<category><![CDATA[dyslipidemia]]></category>
		<category><![CDATA[ecosystem]]></category>
		<category><![CDATA[EliLilly]]></category>
		<category><![CDATA[falciparum]]></category>
		<category><![CDATA[Forest]]></category>
		<category><![CDATA[funding]]></category>
		<category><![CDATA[giant]]></category>
		<category><![CDATA[Glenmark]]></category>
		<category><![CDATA[Glitazar]]></category>
		<category><![CDATA[hibernation]]></category>
		<category><![CDATA[ICMR]]></category>
		<category><![CDATA[India]]></category>
		<category><![CDATA[infrastructure]]></category>
		<category><![CDATA[innovation]]></category>
		<category><![CDATA[investments]]></category>
		<category><![CDATA[Jubilant]]></category>
		<category><![CDATA[lab]]></category>
		<category><![CDATA[Leap]]></category>
		<category><![CDATA[Licensing]]></category>
		<category><![CDATA[Lipaglyn]]></category>
		<category><![CDATA[Lupin]]></category>
		<category><![CDATA[malaria]]></category>
		<category><![CDATA[mass]]></category>
		<category><![CDATA[MNC]]></category>
		<category><![CDATA[NCE]]></category>
		<category><![CDATA[NME]]></category>
		<category><![CDATA[Open]]></category>
		<category><![CDATA[OSDD]]></category>
		<category><![CDATA[Patent]]></category>
		<category><![CDATA[Pharmaceuticals]]></category>
		<category><![CDATA[Piramal]]></category>
		<category><![CDATA[plasmodium]]></category>
		<category><![CDATA[private]]></category>
		<category><![CDATA[public]]></category>
		<category><![CDATA[R&D]]></category>
		<category><![CDATA[Ranbaxy]]></category>
		<category><![CDATA[Ray]]></category>
		<category><![CDATA[Reddy's]]></category>
		<category><![CDATA[research]]></category>
		<category><![CDATA[Rotavac]]></category>
		<category><![CDATA[Sanofi]]></category>
		<category><![CDATA[sector]]></category>
		<category><![CDATA[small]]></category>
		<category><![CDATA[step]]></category>
		<category><![CDATA[Synrium]]></category>
		<category><![CDATA[Tapan]]></category>
		<category><![CDATA[Torrent]]></category>
		<category><![CDATA[universities]]></category>
		<category><![CDATA[value]]></category>
		<category><![CDATA[WHO]]></category>
		<category><![CDATA[wockhardt]]></category>
		<category><![CDATA[Zydus]]></category>

		<guid isPermaLink="false">http://www.tapanray.in/?p=3530</guid>
		<description><![CDATA[It almost went unnoticed by many, when in the post product patent regime, Ranbaxy launched its first homegrown ‘New Drug’ of India, Synriam, on April 25, 2012, coinciding with the ‘World Malaria Day’. The drug is used in the treatment &#8230; <a href="http://www.tapanray.in/rd-is-indian-pharma-moving-up-the-value-chain/">Continue reading <span class="meta-nav">&#8594;</span></a>]]></description>
		<wfw:commentRss>http://www.tapanray.in/rd-is-indian-pharma-moving-up-the-value-chain/feed/</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
	</channel>
</rss>
